MY-T Bio

My-T Bio is a Belgian biotechnology company pioneering the development of off-the-shelf allogeneic T-cell therapies for cancer. Spun out from Ghent University and VIB in 2023, the company leverages its proprietary My-T platform to generate highly functional T cells from healthy donors that can be administered to any patient. This approach seeks to overcome the manufacturing hurdles and high costs associated with patient-specific autologous therapies. My-T Bio's technology focuses on specific T-cell subsets designed for superior infiltration and activity within the tumor microenvironment. The company is currently advancing its lead programs through preclinical development to address unmet needs in oncology.